

ASX Announcement

25 February 2025

1H FY25 Results and Investor Webinar Notification

Genetic Signatures Limited [ASX:GSS] (“GSS” or “Company”), a global molecular diagnostics company will release its 1H FY25 results on Wednesday, 26 February 2025.

The Company will host an investor webinar at 3.00pm (AEDT) on Wednesday, 26 February 2025 where Chief Executive Officer, Allison Rossiter and Chief Financial Officer, Karl Pechmann will discuss the results.

To register for the investor webinar and pre-submit your questions, please visit the link below: https://us06web.zoom.us/webinar/register/WN_M19A3hzFSLaXTBWBgIGCVQ

– END –

Announcement authorised for release by the Company Secretary of Genetic Signatures Limited.

For further information, see our website (www.geneticsignatures.com) or contact us:

Allison Rossiter
Chief Executive Officer

allison.rossiter@geneticsignatures.com

T: +61 (0)2 9870 7580

Karl Pechmann
Chief Financial Officer

karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures’ proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.